You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Affinivax, Astellas’ pneumococcal vaccine wins breakthrough therapy status

Affinivax and Astellas’ pneumococcal vaccine candidate ASP3772 has been granted a breakthrough therapy designation by the US Food and Drug Administration (FDA), the companies announced earlier this week.